Pulmatrix reports Q1 EPS 23c vs ($1.22) last year

Reports Q1 revenue $5.885M vs $1.499M last year. Ted Raad, Chief Executive Officer of Pulmatrix, commented, “Our focus in the first quarter has been to continue our cost saving measures including the wind down of the Phase 2b study for PUR1900 and on strategic alternatives that leverage the potential of PUR3100, iSPERSE technology and our extended cash resources.”